Mándi A, Wilde W, Galgóczy G, Aurich R, Galambos E
Arzneimittelforschung. 1977;27(12):64-6.
According to a uniform trial procedure, the broncholytic efficacy of the new beta2-adrenergic 7-(3-[2-(3,5-dihydroxyphenyl)-2-hydroxy-ethylamino]-propyl)-theophylline (reproterol, Bronchospasmin) was tested in a total of 21 patients afflicted with airways obstruction in two lungfunction laboratories. The IGV, Ras and SGaw were calculated by bodyplethysmography before and 1,3 and 5 min following of 2 puffs from an aerosol container. Excellent and highly significantly bronchodilation was shown already 1 min post inhalation, which further increased during testing time and with which results of subjective criteria for dyspnoeic changes correspond. The preparation may therefore be recommended for therapy of dyspnoeic attacks in an aerosol form equipped with metering valves.
按照统一的试验程序,在两个肺功能实验室对21例患有气道阻塞的患者测试了新型β2 - 肾上腺素能药物7-(3-[2-(3,5 - 二羟基苯基)-2 - 羟乙氨基]-丙基)-茶碱(瑞普特罗,支气管解痉素)的支气管溶解疗效。通过体容积描记法在从气雾剂容器吸入2喷药之前以及之后1、3和5分钟计算IGV、Ras和SGaw。吸入后1分钟即显示出极佳且高度显著的支气管扩张,在测试期间进一步增强,并且与呼吸困难变化的主观标准结果相符。因此,对于配备计量阀的气雾剂形式治疗呼吸困难发作,该制剂值得推荐。